Her2 (ERBB2) Mouse Monoclonal Antibody (HRP conjugated) [Clone ID: 16F12-11]

CAT#: TA808711BM

HER2 (ERBB2) Mouse Monoclonal Antibody, clone 16F12-11, HRP conjugated

Conjugation: Unconjugated Biotin HRP



  View other "16F12-11" antibodies (3)

Need it in bulk or conjugated?
Get a free quote

CNY 3,990.00


货期*
2周

规格
    • 100 ul

Product images

经常一起买 (3)
beta Actin Mouse Monoclonal Antibody, Clone OTI1, Loading Control
    • 30 ul

CNY 300.00
CNY 1,430.00


Recombinant protein of human v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) (ERBB2), transcript variant 1, 20 µg
    • 20 ug

CNY 2,900.00


Transient overexpression lysate of v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) (ERBB2), transcript variant 1
    • 100 ug

CNY 4,840.00

Specifications

Product Data
Clone Name 16F12-11
Applications FC
Recommend Dilution FC: 1:50
Reactivity Human, Mouse, Rat
Host Mouse
Clonality Monoclonal
Immunogen HER2 extracellular domain (aa 23-652) expressed in HEK293 cells with a C-terminal DDK tag
Formulation PBS (pH 7.4) containing 1% BSA, 50% glycerol.
Concentration 0.5 mg/ml
Purification Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G)
Conjugation HRP
Storage Condition Store at -20°C as received.
Gene Name erb-b2 receptor tyrosine kinase 2
Synonyms CD340; HER-2; HER-2/neu; HER2; MLN 19; NEU; NGL; TKR1
Reference Data
Protein Families Druggable Genome, Protein Kinase, Transmembrane
Protein Pathways Adherens junction, Bladder cancer, Calcium signaling pathway, Endometrial cancer, ErbB signaling pathway, Focal adhesion, Non-small cell lung cancer, Pancreatic cancer, Pathways in cancer, Prostate cancer
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Other Versions

Customer Reviews 
Loading...